Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: MWG Biotech To Sell Dharmacon s Synthetic RNA

NEW YORK, May 7-The research tool company MWG Biotech said last week that it will resell RNA synthesis products, services and technologies manufactured by Dharmacon Research, Inc.

 

The agreement covers markets worldwide, and is the first in an expected series of technical and marketing collaborations between the two companies.

 

This deal combines MWG Biotech's expertise in synthetic nucleic acid development and sale with Dharmacon's synthetic RNA products, allowing the two companies to expand their products and services, said MWG Biotech CEO Matthias Schonermark in a statement.

 

Dharmacon specializes in manufacturing synthetic RNA, used in structural studies and in RNA interference-based gene function research.

 

The Lafayette, Colo. company is privately owned.

 

MWG Biotech, based in Ebersberg, Germany, is a major manufacturer of synthetic DNA.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.